Savara Inc
About Savara Inc
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $257.0K
- Net income
- -$118.8M
- Total assets
- $253.4M
- Market cap
- $1.0B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $123.5M
- Operating income
- -$123.5M
- Income tax
- $0
- Net income
- -$118.8M
- EPS (basic)
- $-0.53
- EPS (diluted)
- $-0.53
Balance sheet
- Total assets
- $253.4M
- Current assets
- $241.6M
- Total liabilities
- $50.3M
- Current liabilities
- $20.4M
- Shareholders’ equity
- -$87.0K
Cash flow
- Operating cash flow
- -$101.0M
- Investing cash flow
- -$18.4M
- Financing cash flow
- $137.8M
- Net cash flow
- $18.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.0B
- EPS (diluted)
- $-0.53
- Shares outstanding
- 204.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 18, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $118.8M in FY2020.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Savara Inc.
Write a review
News about Savara Inc
News & sentiment via Polygon.io
